Published in World J Gastroenterol on April 07, 2014
HCV replication in gastrointestinal mucosa: Potential extra-hepatic viral reservoir and possible role in HCV infection recurrence after liver transplantation. PLoS One (2017) 0.76
Response-Guided Therapy for Hepatitis C Virus Recurrence Based on Early Protocol Biopsy after Liver Transplantation. J Korean Med Sci (2015) 0.75
Hepatitis C Recurrence after Orthotopic Liver Transplantation: Mechanisms and Management. J Clin Transl Hepatol (2014) 0.75
Genetic variation in IL28B predicts hepatitis C treatment-induced viral clearance. Nature (2009) 26.47
Boceprevir for untreated chronic HCV genotype 1 infection. N Engl J Med (2011) 19.01
Response-guided telaprevir combination treatment for hepatitis C virus infection. N Engl J Med (2011) 6.31
The association between hepatitis C infection and survival after orthotopic liver transplantation. Gastroenterology (2002) 4.98
Fibrosis progression after liver transplantation in patients with recurrent hepatitis C. J Hepatol (2004) 3.56
Safety and efficacy of protease inhibitors to treat hepatitis C after liver transplantation: a multicenter experience. J Hepatol (2013) 3.36
Effect of telaprevir on the pharmacokinetics of cyclosporine and tacrolimus. Hepatology (2011) 2.95
Cyclosporin A suppresses replication of hepatitis C virus genome in cultured hepatocytes. Hepatology (2003) 2.76
Age-related changes in liver structure and function: Implications for disease ? Exp Gerontol (2005) 2.49
Contribution of donor age to the recent decrease in patient survival among HCV-infected liver transplant recipients. Hepatology (2002) 2.37
Systematic review of the treatment of established recurrent hepatitis C with pegylated interferon in combination with ribavirin. J Hepatol (2008) 2.33
Slowly tapering off steroids protects the graft against hepatitis C recurrence after liver transplantation. Liver Transpl (2002) 2.18
Hepatitis C virus kinetics during and immediately after liver transplantation. Hepatology (2002) 2.15
Recurrent and acquired hepatitis C viral infection in liver transplant recipients. Gastroenterology (1992) 2.09
Efficacy of antiviral therapy on hepatitis C recurrence after liver transplantation: a randomized controlled study. Gastroenterology (2007) 2.07
Predictors of patient and graft survival following liver transplantation for hepatitis C. Hepatology (1998) 1.95
Cyclosporine suppresses hepatitis C virus in vitro and increases the chance of a sustained virological response after liver transplantation. Liver Transpl (2006) 1.86
Sustained virological response to antiviral therapy reduces mortality in HCV reinfection after liver transplantation. J Hepatol (2006) 1.86
Report of the first International Liver Transplantation Society expert panel consensus conference on liver transplantation and hepatitis C. Liver Transpl (2003) 1.86
PHOENIX: A randomized controlled trial of peginterferon alfa-2a plus ribavirin as a prophylactic treatment after liver transplantation for hepatitis C virus. Liver Transpl (2011) 1.85
Impact of donor and recipient IL28B rs12979860 genotypes on hepatitis C virus liver graft reinfection. J Hepatol (2010) 1.82
Hepatic steatosis and its relationship to transplantation. Liver Transpl (2002) 1.78
Histologic recurrence of chronic hepatitis C virus in patients after living donor and deceased donor liver transplantation. Liver Transpl (2004) 1.76
Patient and graft survival in hepatitis C recipients after adult living donor liver transplantation in the United States. Liver Transpl (2004) 1.74
A longitudinal analysis of hepatitis C virus replication following liver transplantation. Gastroenterology (1996) 1.65
Hepatitis C recurrence is more severe after living donor compared to cadaveric liver transplantation. Hepatology (2004) 1.65
Sustained virologic response to therapy of recurrent hepatitis C after liver transplantation is related to early virologic response and dose adherence. Liver Transpl (2007) 1.61
Association of multispecific CD4(+) response to hepatitis C and severity of recurrence after liver transplantation. Gastroenterology (1999) 1.59
Interleukin-28B polymorphisms are associated with histological recurrence and treatment response following liver transplantation in patients with hepatitis C virus infection. Hepatology (2011) 1.59
Sofosbuvir and daclatasvir combination therapy in a liver transplant recipient with severe recurrent cholestatic hepatitis C. Am J Transplant (2013) 1.58
Impact of donor graft steatosis on overall outcome and viral recurrence after liver transplantation for hepatitis C virus cirrhosis. Liver Transpl (2009) 1.55
Early high peak hepatitis C viral load levels independently predict hepatitis C-related liver failure post-liver transplantation. Liver Transpl (2009) 1.50
Living donor liver transplantation for hepatitis C-related cirrhosis: no difference in histological recurrence when compared to deceased donor liver transplantation recipients. Liver Transpl (2006) 1.48
Cyclosporine versus tacrolimus treated liver transplant recipients with chronic hepatitis C: outcomes analysis of the UNOS/OPTN database. Am J Transplant (2011) 1.47
CC genotype donors for the interleukin-28B single nucleotide polymorphism are associated with better outcomes in hepatitis C after liver transplant. Liver Int (2012) 1.46
European collaborative study on factors influencing outcome after liver transplantation for hepatitis C. European Concerted Action on Viral Hepatitis (EUROHEP) Group. Gastroenterology (1999) 1.38
Quantitation of hepatitis C virus RNA in liver transplant recipients. Gastroenterology (1994) 1.37
Cyclosporin versus tacrolimus for liver transplanted patients. Cochrane Database Syst Rev (2006) 1.29
Hepatitis C virus therapy in liver transplant recipients: response predictors, effect on fibrosis progression, and importance of the initial stage of fibrosis. Liver Transpl (2008) 1.27
Severity of liver disease in liver transplantation recipients with hepatitis C virus infection: relationship to genotype and level of viremia. Hepatology (1996) 1.19
Interferon-alpha 2b plus ribavirin in patients with chronic hepatitis C after liver transplantation: a randomized study. Gastroenterology (2003) 1.19
Donor livers with steatosis are safe to use in hepatitis C virus-positive recipients. Liver Transpl (2009) 1.18
Old age and the hepatic sinusoid. Anat Rec (Hoboken) (2008) 1.14
Mycophenolic acid inhibits hepatitis C virus replication and acts in synergy with cyclosporin A and interferon-alpha. Gastroenterology (2006) 1.10
Hepatitis C virus-infected women have a higher risk of advanced fibrosis and graft loss after liver transplantation than men. Hepatology (2011) 1.09
Immunosuppression and HCV recurrence after liver transplantation. J Hepatol (2011) 1.09
Hepatitis C recurrence after liver transplantation: Viral and histologic response to full-dose PEG-interferon and ribavirin. Am J Transplant (2006) 1.09
Short-term prednisone therapy affects aminotransferase activity and hepatitis C virus RNA levels in chronic hepatitis C. Gastroenterology (1994) 1.09
Benefit of sustained virological response to combination therapy on graft survival of liver transplanted patients with recurrent chronic hepatitis C. Am J Transplant (2005) 1.08
Telaprevir-based triple therapy in liver transplant patients with hepatitis C virus: a 12-week pilot study providing safety and efficacy data. Liver Transpl (2012) 1.08
One-year protocol liver biopsy can stratify fibrosis progression in liver transplant recipients with recurrent hepatitis C infection. Liver Transpl (2004) 1.07
Applicability, tolerability and efficacy of preemptive antiviral therapy in hepatitis C-infected patients undergoing liver transplantation. Am J Transplant (2005) 1.06
Risk factors for hepatitis C recurrence after liver transplantation. J Viral Hepat (2007) 1.04
Significant improvement in the outcome of HCV-infected transplant recipients by avoiding rapid steroid tapering and potent induction immunosuppression. J Hepatol (2006) 1.03
Early identification of recipients with progressive histologic recurrence of hepatitis C after liver transplantation. Hepatology (2000) 1.02
Prednisolone suppresses the function and promotes apoptosis of plasmacytoid dendritic cells. Am J Transplant (2006) 1.01
Antiviral treatment of recurrent hepatitis C after liver transplantation: predictors of response and long-term outcome. Transplantation (2009) 1.00
A prospective evaluation of fibrosis progression in patients with recurrent hepatitis C virus following liver transplantation. Liver Transpl (2007) 0.99
In vitro effects of cyclosporine A and tacrolimus on regulatory T-cell proliferation and function. Transplantation (2012) 0.99
A randomized study comparing ribavirin and interferon alfa monotherapy for hepatitis C recurrence after liver transplantation. Hepatology (1998) 0.98
Clinical and histological efficacy of pegylated interferon and ribavirin therapy of recurrent hepatitis C after liver transplantation. Liver Transpl (2006) 0.98
A randomized, multicenter study comparing steroid-free immunosuppression and standard immunosuppression for liver transplant recipients with chronic hepatitis C. Liver Transpl (2011) 0.97
Interferon-alpha for prophylaxis of recurrent viral hepatitis C in liver transplant recipients: a prospective, randomized, controlled trial. Transplantation (1998) 0.97
Sustained viral response to interferon and ribavirin in liver transplant recipients with recurrent hepatitis C. Liver Transpl (2004) 0.96
Treatment of established recurrent hepatitis C in liver-transplant recipients with pegylated interferon-alfa-2b and ribavirin therapy. Transplantation (2004) 0.94
Impact of steroids on hepatitis C virus replication in vivo and in vitro. Ann N Y Acad Sci (2007) 0.94
Randomized, multicenter trial comparing tacrolimus plus mycophenolate mofetil to tacrolimus plus steroids in hepatitis C virus-positive recipients of living donor liver transplantation. Liver Transpl (2013) 0.94
Ageing and the liver. Acta Gastroenterol Belg (2006) 0.93
Combination of interferon alfa-2b and ribavirin in liver transplant recipients with histological recurrent hepatitis C. Liver Transpl (2002) 0.90
Pathogenesis of hepatitis C virus recurrence in the liver allograft. Liver Transpl (2002) 0.89
Effect of calcineurin inhibitors in the outcome of liver transplantation in hepatitis C virus-positive recipients. Transplantation (2010) 0.89
Preemptive therapy for hepatitis C virus after living-donor liver transplantation. Transplantation (2004) 0.89
Prevention of recurrent hepatitis C after liver transplantation with early interferon and ribavirin treatment. Transplant Proc (2001) 0.89
The use of cyclosporine for recurrent hepatitis C after liver transplant: a randomized pilot study. Dig Dis Sci (2010) 0.88
Effect of macrovescicular steatosis and other donor and recipient characteristics on the outcome of liver transplantation. Clin Transplant (2001) 0.88
Serum HCV RNA levels assessed by quantitative NASBA: stability of viral load over time, and lack of correlation with liver disease. The Trent HCV Study Group. J Hepatol (1996) 0.88
Impact of pegylated interferon alpha-2B and ribavirin on hepatic fibrosis in liver transplant patients with recurrent hepatitis C: an open-label series. Liver Int (2006) 0.87
Liver biopsy, viral kinetics, and the impact of viremia on severity of hepatitis C virus recurrence. Liver Transpl (2003) 0.87
Efficacy of antiviral therapy for hepatitis C after liver transplantation with cyclosporine and tacrolimus: a systematic review and meta-analysis. Liver Transpl (2013) 0.85
Cost-effectiveness analysis of antiviral treatment in liver transplant recipients with HCV infection. Transpl Int (2013) 0.84
Assessment of correlation between serum titers of hepatitis C virus and severity of liver disease. World J Gastroenterol (2004) 0.84
Mild donor liver steatosis has no impact on hepatitis C virus fibrosis progression following liver transplantation. Liver Int (2007) 0.83
Factors influencing the progression of fibrosis in patients with recurrent hepatitis C after liver transplantation under antiviral therapy: a retrospective analysis of 939 liver biopsies in a single center. Liver Transpl (2007) 0.82
Completely steroid-free immunosuppression in liver transplantation: a randomized study. Clin Transplant (2013) 0.81
Effect of nonviral factors on hepatitis C recurrence after liver transplantation. Ann Surg (2006) 0.80
Comparative analysis of hepatitis C recurrence and fibrosis progression between deceased-donor and living-donor liver transplantation: 8-year longitudinal follow-up. Transplantation (2011) 0.80
Daily interferon therapy for hepatitis C virus infection in liver transplant recipients. Transplantation (2001) 0.80
Influence of antiviral therapy in the long-term outcome of recurrent hepatitis C virus infection following liver transplantation. Transpl Infect Dis (2013) 0.80
A longitudinal analysis of T-cell epitope-coding regions of hepatitis C virus after liver transplantation. Transplantation (2002) 0.79
Long-term histological effects of preemptive antiviral therapy in liver transplant recipients with hepatitis C virus infection. Liver Transpl (2008) 0.79
Early detection of hepatitis C allograft reinfection after orthotopic liver transplantation: a molecular and histologic study. Mod Pathol (2000) 0.79
Sustained clearance of serum hepatitis C virus-RNA independently predicts long-term survival in liver transplant patients with recurrent hepatitis C. Transplantation (2008) 0.79
Recipient interleukin-28B Rs12979860 C/T polymorphism and acute cellular rejection after liver transplantation: role of the calcineurin inhibitor used. Transplantation (2012) 0.78
[Inhibition of hepatitis C virus replication by mycophenolic acid in hepatocytes]. Zhonghua Shi Yan He Lin Chuang Bing Du Xue Za Zhi (2013) 0.76